In this context, weight loss represents a valuable complementary strategy for modifying PsA, encompassing dietary changes, exercise, as well as emerging weight-loss treatments, such as GLP1-RAs and sodium-glucose co-transporter 2 inhibitors (SGLT2i) in patients with concomitant MetS [51]. Here, GLP1R is linked to metabolic syndrome.